Study of type 1 vascular adhesion molecules in patients with acute myocardial infarction with ST segment elevation at different body weights
https://doi.org/10.21886/2712-8156-2021-2-4-43-49
Abstract
Objective: to study the level of adhesion molecules in patients with STEMI with different BMI at the hospital stage and 12 months after the index event.
Materials and methods: the study included 126 people with STEMI who had undergone PCI and 27 people in the control group. The analysis of the level of svcam‑1 in peripheral blood at the beginning of the disease and after 12 months was carried out, BMI and waist volume were measured. An assessment of the nature and frequency of complications after STEMI was performed.
Results: the levels of biomarkers of the vascular endothelial adhesion molecule type 1 increase during the acute period of stemi, statistically signifi tly decrease, but remain increased by 3.5 times 12 months after the index event compared with the initial values. There was no association of VCAM‑1 with visceral obesity in the groups of our patients. Vascular endothelial adhesion molecules of type 1 increase in patients with a fatal outcome, as well as with an increase in the severity of OSN and CHF. Thus, VCAM 1 can be a predictor of an unfavorable outcome of AMI.
Conclusions: the article presents the study of a marker of systemic inflammation VCAM‑11 in patients with STEMI with various types of obesity or BMI at the stage of hospitalization and outpatient follow‑up during the year. The determination of the VCAM‑1 level can be used to assess the intensity of the inflammatory process and the risk of adverse outcomes.
About the Authors
I. N. Zakovryashina
Rostov State Medical University
Russian Federation
Russian Federation
Irina N. Zakovryashina, Postgraduate student of the Department of Therapy
Rostov-on-Don
L. A. Khaisheva
Rostov State Medical University
Russian Federation
Russian Federation
Larisa A. Khaisheva, Dr. Sci. (Med.), Professor of the Department of Therapy
Rostov-on-Don
S. V. Shlyk
Rostov State Medical University
Russian Federation
Russian Federation
Sergey V. Shlyk, Dr. Sci. (Med.), Head of the Department of Therapy
Rostov-on-Don
I. A. Garina
Rostov State Medical University
Russian Federation
Russian Federation
Irina A. Garina, Cand. Sci. (Med.), Assistant of the Department of Therapy
Rostov-on-Don
References
1. Безверхов А. А., Ищенко О. Ю. Динамика смертности от сердечно-сосудистых заболеваний за период 2015– 2019 гг. Norwegian Journal of Development of the International Science. 2021; (54–2):35–38. DOI: 10.24412/3453-9875-2021-54-2-35-38
2. Самородская И. В., Барбараш О. Л., Кашталап В. В., Старинская М. А. Анализ показателей смертности от инфаркта миокарда в Российской Федерации в 2006 и 2015 годах. Российский кардиологический журнал. 2017; (11):22–26. DOI: 10.15829/1560-4071-2017-11-22-26
3. Российские клинические рекомендации: Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы 2020 г. – 157 с.
4. Гусова З. Р., Дзантиева Е. О. Роль висцерального ожирения и дефицита тестостерона в формировании метаболических нарушений у мужчин. Вестник урологии. 2019;7 (3):14–22. DOI: 10.21886/2308-6424-2019-7-3-14-22
5. De Cosio FG, Diaz-Apodaca B, Baker A, Cifuentes MP, ojedacasares H, Constandce D, et al. US Obesity Mortality Trends and Associated Noncommunicable Diseases Contributing Conditions Among White, Black, and Hispanic Individuals by Age from 1999 to 2017. SN Compr Clin Med. 2021:1–10. DOI: 10.1007/s42399-021-00850-2. Epub ahead of print. PMID: 33842841; PMCID: PMC8020827.
6. Жито А. В., Беленков Ю. Н., Привалова Е. В., Юсупова А. О., Кожевникова М. В., Щендрыгина А. А. Структурные нарушения микроциркуляции у пациентов с ИБС в сочетании с СД 2-го типа и без него. Матер. XXII Научно-практической конференции «Российская наука в современном мире» (Москва, 29 мая 2019 г.). М.: НИЦ «Актуальность РФ», 2019.
7. Kashtalap V., Fedorova N., German A., Pecherina T., Kokov A., Brel N., et al. Lipid metabolism disorders in myocardial infarction patients with preserved left ventricular ejection fraction depending on the presence of obesity. Atherosclerosis. 2018; (275): e247–e248. Doi: 10.1016/j.Atherosclerosis.2018.06.787
8. Жито А. В., Юсупова А. О., Привалова Е. В., Хабарова Н. В., Беленков Ю. Н. Маркеры эндотелиальной дисфункции: Е-селектин, эндотелин-1 и фактор фон Виллебранда у пациентов с ишемической болезнью сердца, в том числе, в сочетании с сахарным диабетом 2 типа. Рациональная Фармакотерапия в Кардиологии. 2019;15 (6):892–899. DOI: 10.20996/1819-6446-2019-15-6-892-899
9. Ахмедов В. А., Шевченко А. С., Исаева А. С. Современные взгляды на факторы возникновения и прогрессирования атеросклероза. РМЖ. Медицинское обозрение. 2019;1 (II):57–62.
10. Kunutsor SK, Bakker SJL, Dullaart RPF. Soluble Vascular Cell Adhesion Molecules May be Protective of Future Cardiovascular Disease Risk: Findings from the PREVEND Prospective Cohort Study. J Atheroscler Thromb. 2017;24 (8):804–818. DOI: 10.5551/jat.38836.
11. Москалец О. В. Молекулы клеточной адгезии ICAM-1 и VCAM-1 при инфекционной патологии. Тихоокеанский медицинский журнал. 2018; (2):21–25. DOI: 10.17238/pmj1609- 1175.2018.2.21-25
12. Мазурина Н. В. Экзогенно-конституциональное ожирение: клинические, гормональные и биохимические параметры персонализация лечения и мониторинга дис.док. Мед.наук: 14.01.02 – Нац мед.. Исследовательский центр эндокринологии. М., 2019 –259 с.
13. Martín Castellanos Á, Cabañas Armesilla MD, Barca Durán FJ, Martín Castellanos P, Gómez Barrado JJ. Obesidad y riesgo de infarto de miocardio en una muestra de varones europeos. El índice cintura-cadera sesga el riesgo real de la obesidad abdominal [Obesity and risk of myocardial infarction in a sample of European males. Waist to-hip-ratio presents information bias of the real risk of abdominal obesity]. Nutr Hosp. 2017;34 (1):88–95. (In Spanish). DOI: 10.20960/nh.982.
14. Герман А. И., Федорова Н. В., Печерина Т. Б., Чернобай А. Г., Груздева О. В., Каретникова В. Н., и др. Влияние ожирения на клиническое течение инфаркта миокарда. РМЖ. Медицинское обозрение. 2019;3 (1 (II)):70–75. Elibrary ID: 38165740
15. Macías C, Villaescusa R, del Valle L, Boffil V, Cordero G, Hernández A, et al. Moléculas de adhesión endoteliales ICAM-1, VCAM-1 y E-selectin en pacientes con síndrome coronario agudo [Endothelial adhesion molecules ICAM-1, VCAM-1 and E-selectin in patients with acute coronary syndrome]. Rev Esp Cardiol. 2003;56 (2):137–44. (In Spanish). DOI: 10.1016/s0300-8932 (03)76837-7.
16. Patel RB, Colangelo LA, Bielinski SJ, Larson NB, Ding J, Allen NB, et al. Circulating Vascular Cell Adhesion Molecule-1 and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis (MESA). J Am Heart Assoc. 2020;9 (22): e019390. DOI: 10.1161/JAHA.120.019390.
17. Fang L, Moore XL, Dart AM, Wang LM. Systemic inflammatory response following acute myocardial infarction. J Geriatr Cardiol. 2015;12 (3):305–12. DOI: 10.11909/j.issn.1671- 5411.2015.03.020.
18. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, et al. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail. 2003;5 (4):507–16. DOI: 10.1016/s1388-9842(03)00009-6.
19. No DOC, Freitas IA, Meneses GC, Martins AMC, Daher EF, Rocha JHC, et al. Interleukin-6 and adhesion molecules VCAM-1 and ICAM-1 as biomarkers of post-acute myocardial infarction heart failure. Braz J Med Biol Res. 2019;52 (12): e8658. DOI: 10.1590/1414-431X20198658.
20. Hayek A, Paccalet A, Mechtouff L, Da Silva CC, Ivanes F, Falque H, et al. Kinetics and prognostic value of soluble VCAM-1 in ST-segment elevation myocardial infarction patients. Immun Inflamm Dis. 2021;9 (2):493–501. DOI: 10.1002/iid3.409.
21. Radecke CE, Warrick AE, Singh GD, Rogers JH, Simon SI, Armstrong EJ. Coronary artery endothelial cells and microparticles increase expression of VCAM-1 in myocardial infarction. Thromb Haemost. 2015;113 (3):605–16. DOI: 10.1160/TH14-02-0151.
22. Yip HK, Wu CJ, Hang CL, Chang HW, Yang CH, Hsieh YK, et al. Levels and values of inflammatory markers in patients with angina pectoris. Int Heart J. 2005;46 (4):571–81. DOI: 10.1536/ihj.46.571.
23. Корой П. В., Сляднев С. А., Ягода А. В. Взаимосвязь метаболического синдрома с молекулами адгезии при неалкогольной жировой болезни печени. Медицинский вестник Северного Кавказа. 2020;15 (1):23–27. DOI: 10.14300/mnnc.2020.15004
24. Kunutsor SK, Bakker SJL, Dullaart RPF. Soluble Vascular Cell Adhesion Molecules May be Protective of Future Cardiovascular Disease Risk: Findings from the PREVEND Prospective Cohort Study. J Atheroscler Thromb. 2017;24 (8):804–818. DOI: 10.5551/jat.38836.
Review
For citations:
Zakovryashina I.N., Khaisheva L.A., Shlyk S.V., Garina I.A. Study of type 1 vascular adhesion molecules in patients with acute myocardial infarction with ST segment elevation at different body weights. South Russian Journal of Therapeutic Practice. 2021;2(4):43-49. (In Russ.) https://doi.org/10.21886/2712-8156-2021-2-4-43-49
Views:
656
Email this article 